Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company provides support to medical practitioners through training, practice development, and operational services to establish and manage hormone therapy centers. Its activities include educating practitioners on identifying and treating hormone-related conditions. The company generates revenues by charging the Biote-partnered clinics fees associated with the Biote Method and from the sale of Biote-branded dietary supplements.
Last trade$0.9801
Day change+$0.0198 (+2.06%)
Day range$0.97 – $1.01
Volume46,580
Market cap$26M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$25.96M
Price / earnings
—
Price / book
-0.4×
Price / sales
0.15×
EV / sales
0.77×
EV / EBITDA
10.64×
Profitability
Earnings per share
-$0.07
Return on assets
-1.89%
Return on equity
2.95%
Dividend yield
4.5%
Liquidity and leverage
Debt / equity
-1.84×
Current ratio
1.37×
Quick ratio
0.79×
Cash ratio
0.29×
Cash flow
Price / cash flow
1.86×
Price / free cash flow
4.24×
Free cash flow
$6.12M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for BTMD, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$43.33M
$44.23M
$44.94M
$46.41M
$47.96M
$48.86M
$48.99M
$49.83M
Cost of revenue
$14M
$15.31M
$13.98M
$14.84M
$13.54M
$13.88M
$12.61M
$14.04M
Gross profit
$29.33M
$28.92M
$30.95M
$31.57M
$34.42M
$34.99M
$36.38M
$35.8M
Selling, general and administrative
$26.84M
$32.43M
$27.79M
$24.74M
$26.15M
$24.22M
$26.69M
$33.03M
Research and development
$0
$0
$0
$0
$0
$0
$0
$0
Total operating expenses
$26.84M
$33.07M
$27.79M
$24.74M
$26.15M
$24.22M
$26.69M
$33.03M
Operating income
$2.49M
-$4.16M
$3.17M
$6.83M
$8.27M
$10.77M
$9.69M
$2.77M
Interest expense
-$2.12M
-$2.18M
$0
$0
-$2.73M
-$2.85M
$0
$0
Income before taxes
$1.37M
-$7.13M
$3.34M
$5.6M
$8.45M
$6.08M
$17.46M
-$1.22M
Income taxes
$796K
$296K
$662K
$2.99M
-$765K
$2.15M
$1.62M
-$4.7M
Net income
$569K
-$7.43M
$2.68M
$2.62M
$9.22M
$3.93M
$15.84M
$3.48M
Net income attributable to common shareholders
$407K
-$6.56M
$2.28M
$1.95M
$8.19M
$3.19M
$13.72M
$3.7M
EBITDA
$3.52M
-$2.55M
$4.15M
$7.78M
$9.22M
$11.68M
$10.55M
$3.91M
Basic earnings per share
$0.01
-$0.23
$0.07
$0.06
$0.26
$0.10
$0.44
$0.10
Diluted earnings per share
$0.01
-$0.23
$0.06
$0.05
$0.22
$0.10
$0.37
$0.10
Recent news
Company coverage with links to the original publishers.
biote reported Q3 2026 results with a 9.6% year-over-year revenue decline to $43.3 million, attributed to a January 2026 product recall that delayed clinic onboarding. Despite this, the company maintains full-year 2026 revenue guidance above $175 million. Management is deploying data analytics to support underperforming clinics, standardizing medical training to retain practitioners, and ramping up internal manufacturing at Xteria Health to restore gross margins, with early signs of procedure volume stabilization.
biote Corp. (BTMD) reported quarterly earnings of $0.01 per share, beating the consensus estimate of -$0.05 loss by 120%, but missed revenue expectations at $43.33 million versus the estimated $44.13 million. The stock has declined 56.9% year-to-date and carries a Zacks Rank #3 (Hold) rating. The Medical-Products industry ranks in the bottom 37% of Zacks industries.
The article highlights four stocks - Steelcase, Carriage Services, biote, and Acme United - that have seen rising cash flows, making them good investment options. The article emphasizes the importance of analyzing a company's cash position and net cash flow as indicators of financial health and growth potential.
The article suggests that stocks with rising cash flows, such as Ardmore Shipping Corporation, TXO Partners, L.P., GeoPark Limited, and biote Corp., are worth buying as they have the flexibility to weather market uncertainties and support growth. The article emphasizes the importance of analyzing a company's cash-generating efficiency to assess its true financial health.
Haemonetics is benefiting from growth in its Plasma, Hospital, and Hemostasis Management segments, driven by new product launches and market share gains. The company's hospital portfolio is evolving, creating new growth opportunities. However, it faces challenges from inflationary pressures and supply chain disruptions.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.